Psoriatic Arthritis

The European Commission has extended approval for Celltrion Healthcare’s subcutaneous infliximab biosimilar to treat adults with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.

The FDA has approved guselkumab, an interleukin-23 receptor inhibitor, for the treatment of adult patients with active psoriatic arthritis, according to a company press release from Janssen Pharmaceuticals.

Synovitis, acne, pustulosis, hyperostosis, osteomyelitis — collectively known as SAPHO syndrome — in pustular psoriasis remains for most rheumatologists a rare enigma with an unclear pathogenesis, according to Philip Helliwell, PhD, DM, BM BCh, FRCP, MA, of the University of Leeds.

The incidence and severity of COVID-19 among patients with rheumatic disease treated with targeted synthetic or biological DMARDs is consistent with those in the general population, according to data published in Arthritis & Rheumatology.

The FDA has approved the sixth biosimilar to adalimumab, adalimumab-fkjp, for all eligible indications of the biologic product, according to a company press release.

A U.S. appeals court has ruled in favor of two patents for Amgen’s etanercept against the biosimilar etanercept-szzs from Novartis’ Sandoz, upholding a prior decision validating claims of patent infringement.

Patients with psoriatic arthritis demonstrate a 2.3-fold increased prevalence for systemic lupus erythematosus, compared with the general population, according to data published in The Journal of Rheumatology.

The use of TNF inhibitors among patients with autoimmune disease may be associated with an increased risk for inflammatory central nervous system events, according to data published in JAMA Neurology.

The gap between patient-reported outcomes and clinician-assessed endpoints in rheumatology is well documented. Patients generally care about pain, fatigue and the emotional toll immune-mediated diseases can take, while physicians are more likely to pay attention to interleukin activity or C-reactive protein levels.

Etanercept monotherapy or a combination of etanercept and methotrexate had better psoriasis outcomes than methotrexate alone, according to a poster presented at the American Academy of Dermatology virtual meeting.